Central retinal vein occlusion in patients with metastatic solid tumors on tyrosine kinase inhibitors: a report of case series and literature review

Mingyue Luo, Lu Sun, D. Rongping, Youxin Chen, Chan WuFrontiers in Medicine 2024 · DOI

Abstract

All patients diagnosed with central retinal vein occlusion (CRVO) while on tyrosine kinase inhibitors (TKIs) received dexamethasone implant treatment and achieved a fluid-free macula. This report aims to raise awareness among oncologists regarding the possibility of TKI-related CRVO and the necessity for regular retinal screening by specialists.

Introduction: The Challenge of TKI-Induced Ocular Toxicity

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of metastatic solid tumors by blocking specific signaling pathways, such as the vascular endothelial growth factor (VEGF) pathway. While effective at starving tumors of their blood supply, these targeted therapies can cause unexpected off-target toxicities.

Central retinal vein occlusion (CRVO) is a severe, vision-threatening blockage of the main retinal vein. While rare, it has emerged as a potential adverse effect of TKI therapy. This presents a clinical paradox: the standard treatment for CRVO typically involves local anti-VEGF injections. However, if the condition is triggered by systemic anti-VEGF drugs (TKIs), further local anti-VEGF treatment may be ineffective or even harmful. This study explores alternative treatment strategies, specifically the use of intravitreal dexamethasone implants (IDI).

Methods

The researchers conducted a clinical case series and a comprehensive literature review:

  • Case Series: Documentation of three patients who developed CRVO while receiving TKIs (sorafenib or apatinib) for renal cell carcinoma or thyroid cancer. Clinical data included fundus photography and Optical Coherence Tomography (OCT).
  • Literature Review: Analysis of six previously reported cases of TKI-induced retinal vascular abnormalities to identify commonalities in drug exposure, clinical presentation, and treatment outcomes.

Key Results and Clinical Outcomes

All three patients in the series presented with severe macular edema and significant vision loss. Notably, these patients lacked typical uncontrolled systemic risk factors for CRVO, pointing to TKI therapy as the likely cause.

Retinal and OCT images of Patient 2 showing severe macular edema at presentation (A, B) and resolution five months after IDI treatment (C, D).

A critical finding was the failure of standard therapy in one instance; Patient 3 received an initial injection of ranibizumab (anti-VEGF), which failed to resolve the edema. In contrast, all three patients achieved a fluid-free macula after switching to or starting with intravitreal dexamethasone implants (IDI). While some patients required multiple injections to maintain stability (e.g., Patient 1 required four injections over a 9-month period), the steroid-based approach proved consistently effective where anti-VEGF therapy might falter.

Discussion: The Paradox of Anti-VEGF Therapy

The study highlights a mechanistic conflict in treating TKI-induced CRVO. Systemic VEGF blockade likely causes endothelial dysfunction and subsequent thrombosis. Adding local anti-VEGF agents to an already compromised vascular environment may be counterproductive.

The success of IDIs suggests that inflammation plays a primary role in the pathogenesis of this specific type of CRVO. The authors hypothesize that systemic TKIs disrupt retinal endothelial homeostasis, leading to cell death and a pro-thrombotic state. By using sustained-release steroids, clinicians can address the inflammatory component of the vascular damage more effectively.

Conclusion and Future Directions

While limited by a small sample size and the lack of a formal control group, this study provides vital evidence for managing a rare but serious side effect of cancer therapy. The authors emphasize the need for close collaboration between oncologists and ophthalmologists. Regular retinal screening for patients on TKI therapy is recommended to ensure early detection and appropriate intervention, prioritizing steroid-based treatments over traditional anti-VEGF protocols.

Summary updated

Abstract

All patients diagnosed with CRVO on TKIs received dexamethasone implant treatment and obtained a fluid-free macula. We would like to raise awareness among our colleague oncologists about the possibility of CRVO related to TKI use and the necessity for patients to be screened regularly by a retinal specialist.
BibTeX
@inproceedings{luo2024central,
  author = {Mingyue Luo and Lu Sun and D. Rongping and Youxin Chen and Chan Wu},
  title = {{Central retinal vein occlusion in patients with metastatic solid tumors on tyrosine kinase inhibitors: a report of case series and literature review}},
  booktitle = {Frontiers in Medicine},
  year = {2024},
  doi = {10.3389/fmed.2024.1362108},
}
Figure